Saturday, June 20, 2020 10:28:23 AM
Well good write up - dreaming numbers.
I understand medicine but I understand numbers better.
700 o/s million shares as the basis for calculations.
@$10 - market cap $7 Billion
@ $50 - market cap $35 Billion
@ $100 - market cap $70 Billion
Assuming o/s does not increase which is not the case for most growing biotech.
Now show me how many pharma have $70 B market cap and above and how many years it took them to reach.
If CYDY is going to give revenue in the range you are talking, BP will be just buy them out - remember Medivation, pharmacyclics. Hey even CELG was merged or bought out once they had actual revenues.
So before this reaches $15B - it will be bought out.
Also I do not believe your numbers - you are considering the world - just look at how many years and how many trials it takes for BP to get registration in each new countries. So your timelines are unrealistic in terms of existence of CYDY. This assumes that the drug actually works as good in all indications.
So you live in your dream world and I go with my reality
I understand medicine but I understand numbers better.
700 o/s million shares as the basis for calculations.
@$10 - market cap $7 Billion
@ $50 - market cap $35 Billion
@ $100 - market cap $70 Billion
Assuming o/s does not increase which is not the case for most growing biotech.
Now show me how many pharma have $70 B market cap and above and how many years it took them to reach.
If CYDY is going to give revenue in the range you are talking, BP will be just buy them out - remember Medivation, pharmacyclics. Hey even CELG was merged or bought out once they had actual revenues.
So before this reaches $15B - it will be bought out.
Also I do not believe your numbers - you are considering the world - just look at how many years and how many trials it takes for BP to get registration in each new countries. So your timelines are unrealistic in terms of existence of CYDY. This assumes that the drug actually works as good in all indications.
So you live in your dream world and I go with my reality
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
